Article: article from journal or magazin.
Case report (case report): feedback on an observation with a short commentary.
Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.
Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome.
Adult, Biopsy, Decompressive Craniectomy/methods, Demyelinating Diseases/chemically induced, Demyelinating Diseases/diagnosis, Demyelinating Diseases/</QualifierName> <QualifierName MajorTopicYN="Y" UI="Q000601">, Encephalitis/chemically induced, Encephalitis/diagnosis, Encephalitis/</QualifierName> <QualifierName MajorTopicYN="Y" UI="Q000601">, Etanercept, Humans, Immunoglobulin G/adverse effects, Immunohistochemistry, Immunosuppressive Agents/adverse effects, Magnetic Resonance Imaging, Male, Receptors, Tumor Necrosis Factor, Recovery of Function, Spondylitis, Ankylosing/diagnosis, Spondylitis, Ankylosing/drug therapy, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha/immunology
Last modification date